Vaxil Bio Ltd V.VXL

Alternate Symbol(s): VXLLF

Healthcare Biotechnology

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.

TSXV:VXL - Post by User

Vaxil Bio Ltd > Over 6 week delay to make new Corvax

<< Previous

Bullboard Posts

Next >>

Comment by HIKER2013on Dec 17, 2020 12:20am

74 Views

Post# 32125786

RE:Over 6 week delay to make new Corvax

So why the 6 week delay ? And exactly what do you mean by that.... So after 6 weeks please clarify.................Is this when results expected, trial begins, or what ?

HR

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario